Core Viewpoint - The competition for the代理权 of "童颜针" has intensified, with 江苏吴中 facing significant challenges after its delisting, while 爱美客's performance remains concerning amid ongoing disputes [1][10]. Group 1: 江苏吴中 Developments - 江苏吴中 plans to transfer 100% of its subsidiary, 上海吴中美学, for 80 million yuan to alleviate cash flow issues and address debt pressures [2][3]. - The subsidiary, 上海吴中美学, reported total assets of approximately 104 million yuan and a net loss of about 21.83 million yuan for the period from January to November 2025 [3]. - 江苏吴中 was forced to delist at the end of 2025 due to violations including false disclosures and inflated revenue, with a cumulative inflated revenue of approximately 1.771 billion yuan from 2020 to 2023 [4]. Group 2: 爱美客 Performance - 爱美客's revenue for the first three quarters of 2025 was 1.865 billion yuan, a year-on-year decline of 21.49%, with a net profit decrease of 31.05% to 1.093 billion yuan [10]. - The company experienced a 30.12% drop in net cash flow from operating activities compared to the previous year, amounting to 1.073 billion yuan [10]. Group 3: Industry Context - 江苏吴中 initiated its medical beauty segment in April 2021, aiming to expand its presence in the industry, which included acquiring exclusive distribution rights for the AestheFill product [5][6]. - The partnership with Regen for the AestheFill product faced challenges when 爱美客 acquired a majority stake in Regen, leading to a dispute over distribution rights [8][9].

Core Viewpoint - The dispute over the代理权 of AestheFill (艾塑菲), a high-demand product known as "童颜针," has escalated into a significant arbitration case, with *ST Suwu (600200.SH) seeking damages of up to 1.6 billion yuan against the Korean REGEN company, a subsidiary of Aimeike (爱美客) [1][2][3]. Group 1 - *ST Suwu's subsidiary, Daxiu Medical, has filed for arbitration against Korean REGEN, alleging breach of contract and seeking 1.6 billion yuan in damages [1][3]. - The AestheFill product has generated over 300 million yuan in sales within just eight months, boasting an 82% gross margin, making it a crucial revenue source for *ST Suwu [1][8]. - Aimeike's recent decision to terminate the exclusive distribution agreement with Daxiu Medical has raised concerns about the future of AestheFill's distribution in mainland China [2][3]. Group 2 - Aimeike's revenue growth has been slowing, with a projected revenue of 3.026 billion yuan in 2024, reflecting a mere 5.45% increase compared to over 47% in 2023 [8][9]. - The overall medical aesthetics market in China is expected to grow at a rate of 10% to 15% in the coming years, contrasting with Aimeike's declining performance [9]. - AestheFill's sales accounted for 20.42% of *ST Suwu's total revenue in 2024, significantly contributing to the company's turnaround from losses [9][10].